A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee.

Trial Profile

A Randomised, Double-Blind, Placebo-Controlled, Single- and Multiple-Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MEDI7352 in Subjects With Painful Osteoarthritis of the Knee.

Recruiting
Phase of Trial: Phase I

Latest Information Update: 05 Jun 2017

At a glance

  • Drugs MEDI 7352 (Primary) ; MEDI 7352 (Primary)
  • Indications Osteoarthritis; Pain
  • Focus Adverse reactions
  • Sponsors AstraZeneca
  • Most Recent Events

    • 30 May 2017 Planned End Date changed from 13 Jun 2017 to 30 Jun 2018.
    • 30 May 2017 Planned primary completion date changed from 13 Jun 2017 to 30 Jun 2018.
    • 28 Apr 2016 Planned End Date changed from 1 Feb 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top